Metronidazole Toxicity in Cockayne Syndrome: A Case Series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 26304821.
- Also identified by DOI 10.1542/peds.2015-0531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cockayne syndrome (CS) is a rare genetic disorder characterized by small stature, intellectual disability, and accelerated pathologic aging. Through the Cockayne Syndrome Natural History Study, we have identified 8 cases of acute hepatic failure after metronidazole administration (8% of our cohort), 3 of which were fatal. The interval between initial administration and death was 6 to 11 days. Two of these patients also experienced acute neurologic deficit. Both hepatotoxicity and acute neurologic deficit have been reported previously as extremely rare adverse events after metronidazole administration. However, we have not identified any patients with CS who have received metronidazole without serious adverse effects. We recommend that a diagnosis of CS be considered an absolute contraindication to the use of metronidazole.
Medical subject headings
- Anti-Infective Agents
- Cockayne Syndrome
- Liver Failure, Acute
- Metronidazole